UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): January 16, 2017
BOSTON SCIENTIFIC CORPORATION
(Exact name of registrant as specified in its charter)
|
DELAWARE |
|
1-11083 |
|
04-2695240 |
|
(State or other |
|
(Commission |
|
(IRS employer |
|
jurisdiction of |
|
file number) |
|
identification no.) |
|
incorporation) |
|
|
|
|
|
300 Boston Scientific Way, Marlborough, Massachusetts |
|
01752-1234 |
|
(Address of principal executive offices) |
|
(Zip code) |
Registrant’s telephone number, including area code: (508) 683-4000
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On January 16, 2017, Kristina M. Johnson, Ph.D., informed the Company that she will not stand for re-election at the Company’s 2017 Annual Meeting. Dr. Johnson has served as a member of the Board since January 2011 as well as from April 2006 to May 2009, and currently serves as Chairman of the Executive Compensation and Human Resources Committee and as a member of the Finance Committee. Dr. Johnson will continue to serve as a director and in her committee roles until the 2017 Annual Meeting. Dr. Johnson’s decision not to stand for re-election at the 2017 Annual Meeting is not the result of any disagreement with the Company.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
BOSTON SCIENTIFIC CORPORATION | |
|
|
|
|
|
|
|
|
|
|
|
Date: |
January 20, 2017 |
By: |
/s/ Vance R. Brown |
|
|
|
|
Vance R. Brown |
|
|
|
|
Vice President and Chief Corporate Counsel |